Newsletter | June 24, 2026

06.24.26 -- Advancing CAR T For Drug-Free Remission In Autoimmune Disease With Kyverna Therapeutics' Dr. Naji Gehchan

SPONSOR

Accelerating Genomic Medicine

Traditional cell therapy manufacturing is hitting a logistical plateau that restricts patient access worldwide. Discover how the concept of the body as a bioreactor could shift the paradigm from external engineering to internal healing.

FOCUS ON TRANSLATIONAL RESEARCH

Advancing CAR T For Drug-Free Remission In Autoimmune Disease With Kyverna Therapeutics' Dr. Naji Gehchan

In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna Therapeutics, joins Host Erin Harris to outline the company’s mission to apply CAR-T cell therapy beyond oncology to treat severe autoimmune diseases, highlighting promising Phase 2 data from its investigational therapy, Miv-cel, in stiff person syndrome (SPS).

High-Resolution Sizing Methods For Accurate Cell-Free DNA Analysis

Discover how precise sizing reveals nucleosome patterns in cfDNA. Learn to isolate genuine biological signals from extraction artifacts to ensure highly reliable genomic data interpretation.

Improving Next-Generation Sequencing Workflows With Droplet Digital PCR

Optimize NGS workflows by using digital PCR for absolute quantification. Improve library quality, reduce bias, and gain sensitive validation for rare variants in complex genomic samples.

Finding The Ideal Linear Range For Quantitative Western Blotting

Master how to determine the linear range for western blot quantification using total protein stains or housekeeping proteins to ensure accurate normalization and avoid saturation effects.

Bridging Discovery And CMC With Rapid Pools

Investigate how early stable CHO expression data reveals manufacturability issues in complex antibodies that transient screening misses, with case studies showing how these changes lead to selection.

The Spirit Of MISEV: Establishing Collaborative Research Standards

MISEV guidelines help extracellular vesicle researchers design robust experiments through transparent reporting and rigorous characterization rather than rigid checklists.

A Strategic Overview Of Fc Engineering

Explore how Fc engineering transforms antibodies into precise therapeutic tools by modulating immune effector functions and extending half-life to improve patient outcomes and overcome complex clinical challenges.

SPONSOR

Join Chief Editor Erin Harris for a special Cell & Gene Live discussion with Robert Bell, Ph.D., CSO at Ascidian Therapeutics, and Karen Kozarsky, Ph.D., Founder of Vector BioPartners . Together, they'll explore how capsid engineering affects transduction efficiency, the tradeoffs between tissue specificity and manufacturability, and what manufacturing teams need to know about real-world in vivo performance. Register for Solving Vector Yield Challenges in In Vivo CGT on July 7, 2026 at 11 AM  ET.

TRANSLATIONAL RESEARCH SOLUTIONS

Advance Infectious Disease Research With ddPCR System - Bio-Rad Laboratories, Inc.

Explore A New Imaging System That Offers Faster Scans - LICORbio

Electroporation For Discovery And Screening - MaxCyte, Inc.

A Revolutionary Consumable Empowering High-Throughput Organ-Chip Studies - Emulate

Connect With Cell & Gene: